Biomimetic MAGnetic nanoparticles with homotypic targeting for combinatorial the...
Biomimetic MAGnetic nanoparticles with homotypic targeting for combinatorial theraNOSTICS of triple-negative breast cancers
Cancer is a leading cause of death and is a major impediment to increasing life expectancy around the globe. Amongst all breast cancers (BC), triple-negative breast cancers (TNBCs), are of much concern, as chemotherapy is the only...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-117977RA-I00
NANOPARTICULAS BIOMIMETICAS PARA EL TRATAMIENTO DIRIGIDO DEL...
85K€
Cerrado
RTC-2017-6620-1
nanoHeat - Desarrollo y validación preclínica de un sistema...
657K€
Cerrado
PID2020-112685RB-I00
NANOMEDICINAS BASADAS EN NANOPARTICULAS PARA INMUNOTERAPIA E...
249K€
Cerrado
TheranoXome
Engineered Exosomes for Stimuli-responsive Image-guided Drug...
181K€
Cerrado
MAT2013-42551-P
NANOVECTORES MAGNETICOS PARA CONFINAMIENTO CELULAR E HIPERTE...
74K€
Cerrado
GIULIa
MAGNETIC HYPERTHERMIA FOR METASTASIZED TUMOR TREATMENT AND R...
3M€
Cerrado
Información proyecto MAGNOSTICS
Duración del proyecto: 25 meses
Fecha Inicio: 2023-03-23
Fecha Fin: 2025-05-01
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cancer is a leading cause of death and is a major impediment to increasing life expectancy around the globe. Amongst all breast cancers (BC), triple-negative breast cancers (TNBCs), are of much concern, as chemotherapy is the only option. However, it is associated with chemoresistance owing to drug efflux. Moreover, since TNBCs are negative for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER 2), treatment strategies targeting these receptors do not work. Combined strategies for TNBCs have strong potential in treating TNBCs, as compared to singular approaches. Thus, MAGNOSTICS aims to develop biomimetic cancer cell membrane (CCM) coated magnetic nanoparticles for chemotherapy, gene targeting, and magnetic hyperthermia as a triple strategy for TNBC therapy. In addition, MAGNOSTICS proposes multimodal theranostics incorporating MRI enabled by MNPs. To promote cellular uptake and immune escape, MNPs will be loaded with CDDP and siRNA and camouflaged with CCM derived from TNBC cells. CCM coating will utilize the homotypic targeting strategy for self-recognition and uptake of NPs. Thus, the objectives are; i) to synthesize and characterize CCM coated MNPs conjugated with CDDP and siABCB1, ii) to study the biocompatibility/uptake and single therapeutic strategies as proof-of-concept in 2D cell cultures, iii) To develop 3D multicellular tumor spheroids and demonstrate the effectiveness of camouflaged NPs as combined theranostic platform; iv) to ensure further professional development of the ER through training, dissemination and public engagement. MAGNOSTICS thus aims to improve TNBC treatment and impact society with the right term and place.